BTIG Maintains Buy on LifeMD, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst David Larsen has maintained a Buy rating on LifeMD (NASDAQ:LFMD) and increased the price target from $13 to $14.
April 23, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst David Larsen reaffirmed a Buy rating on LifeMD and raised the price target from $13 to $14.
The increase in price target by BTIG reflects a positive outlook on LifeMD's future performance. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100